Congenital amegakaryocytic thrombocytopenia (CAT) is a rare constitutional marrow failure syndrome characterised by severe thrombocytopenia and the absence of megakaryocytes in the bone marrow. Most patients eventually develop transfusion resistant thrombocytopenia or their disease progresses to frank aplastic anaemia. Conventional treatment is mostly ineffective. Bone marrow transplantation (BMT) can be a curative option. We present here our experience with allogeneic BMT in two patients with CAT. The first patient underwent BMT from her HLA-identical sister at the age of 3.5 years. Conditioning consisted of busulphan + cyclophosphamide + ATG, with cyclosporin and MTX as GVHD prophylaxis. She had an uncomplicated clinical course post-BMT, engrafted with donor cells and showed steadily rising Plt counts. Concomitant to the rise in Plt counts, a reduction in her serum thrombopoietin (TPO) levels was observed. The second patient had no HLA identical sibling and received a matched unrelated transplant. Her conditioning was identical to that of the first patient, but her graft was first depleted of T-cells. There was no engraftment and she was given a second, full graft from the same donor. She did engraft this time but died 3 months after the initial transplant due to invasive pulmonary and hepatic aspergillosis.
